CoChat

Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial

Hygum, Katrine, Harsløf, Torben, Jørgensen, Niklas Rye, Rungby, Jørgen, Pedersen, Steen B., Langdahl, Bente L. · 2020 · Bone
Cited by 75

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND Liraglutide, a glucagon-like peptide-1 receptor agonist, has well known beneficial effects on glucose metabolism, and animal studies indicate that liraglutide also affects bone turnover by decreasing bone resorption. The primary objective of the study was to investigate the effect of liraglutide on bone turnover in patients with T2D. METHODS The study was a randomized, double-blinded, clinical trial. Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks. The primary endpoint was change in p-collagen I cross-linked C-terminal telopeptide (p-CTX). RESULTS P-CTX increased in patients treated with liraglutide by 0.07 (0.03; 0.10) μg/l (p < 0.001) and in patients treated with placebo by 0.03 (0.00; 0.06) μg/l (p = 0.04), however, changes were not different between the groups (p = 0.16). Weight decreased in patients treated with liraglutide from baseline to week four (p < 0.001) and remained stable thereafter. P-procollagen type 1 N-terminal propeptide (P1NP) decreased in patients treated with liraglutide from baseline to week four (p < 0.01), increased between weeks 4 and 13 (p = 0.03), and remained elevated thereafter. Weight and p-P1NP did not change in patients treated with placebo. Hip bone mineral density (BMD) decreased in placebo treated patients from baseline to end of study, whereas no changes were seen in patients treated with liraglutide (p = 0.01 difference between groups). CONCLUSION Liraglutide treatment for 26 weeks did not affect bone resorption and preserved hip BMD despite weight loss in patients with T2D, suggesting that liraglutide has some antiresorptive effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bone.2019.115197

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Holst, 1987, Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut, FEBS Lett., 211, 169, 10.1016/0014-5793(87)81430-8 · DOI · Paper page
  2. Marre, 2009, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU), Diabetic Medicine : A Journal of the British Diabetic Association, 26, 268, 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
  3. Clowes, 2003, Octreotide abolishes the acute decrease in bone turnover in response to oral glucose, J. Clin. Endocrinol. Metab., 88, 4867, 10.1210/jc.2002-021447 · DOI · Paper page
  4. Janghorbani, 2007, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture, Am. J. Epidemiol., 166, 495, 10.1093/aje/kwm106 · DOI · Paper page
  5. Vestergaard, 2007, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 18, 427, 10.1007/s00198-006-0253-4 · DOI · Paper page
  6. Ekstrom, 2013, Health related quality of life, reoperation rate and function in patients with diabetes mellitus and hip fracture--a 2 year follow-up study, Injury, 44, 769, 10.1016/j.injury.2012.10.003 · DOI
  7. Liao, 2014, Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies, Diabetes Care, 37, 2246, 10.2337/dc13-2957 · DOI
  8. Ma, 2012, Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies, Eur. J. Epidemiol., 27, 319, 10.1007/s10654-012-9674-x · DOI · Paper page
  9. Hygum, 2017, Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis, Eur. J. Endocrinol., 176, R137, 10.1530/EJE-16-0652 · DOI · Paper page
  10. Mitchell, 2018, Type 2 Diabetes in relation to hip bone density, area, and bone turnover in Swedish men and women: a cross-sectional study, Calcif. Tissue Int., 103, 501, 10.1007/s00223-018-0446-9 · DOI
  11. Purnamasari, 2017, Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study, BMC Endocr. Disord., 17, 72, 10.1186/s12902-017-0224-0 · DOI
  12. Nuche-Berenguer, 2011, GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia, J. Endocrinol., 209, 203, 10.1530/JOE-11-0015 · DOI · Paper page
  13. Yamada, 2008, The murine glucagon-like peptide-1 receptor is essential for control of bone resorption, Endocrinology, 149, 574, 10.1210/en.2007-1292 · DOI · Paper page
  14. Driessen, 2015, Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs, Calcif. Tissue Int., 97, 506, 10.1007/s00223-015-0037-y · DOI · Paper page
  15. Driessen, 2017, The use of incretins and fractures - a meta-analysis on population-based real life data, Br. J. Clin. Pharmacol., 83, 923, 10.1111/bcp.13167 · DOI
  16. Su, 2015, Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials, Endocrine, 48, 107, 10.1007/s12020-014-0361-4 · DOI · Paper page
  17. Orwoll, 1991, Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/bone study group, J. Bone Miner. Res., 6, 191, 10.1002/jbmr.5650060213 · DOI
  18. Lang, 1999, Assessment of vertebral bone mineral density using volumetric quantitative CT, J. Comput. Assist. Tomogr., 23, 130, 10.1097/00004728-199901000-00027 · DOI · Paper page
  19. Cann, 2014, CTXA hip--an extension of classical DXA measurements using quantitative CT, PLoS One, 9, 10.1371/journal.pone.0091904 · DOI
  20. Sode, 2011, Quantitative characterization of subject motion in HR-pQCT images of the distal radius and tibia, Bone, 48, 1291, 10.1016/j.bone.2011.03.755 · DOI
  21. Boutroy, 2005, In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography, J. Clin. Endocrinol. Metab., 90, 6508, 10.1210/jc.2005-1258 · DOI · Paper page
  22. Hansen, 2013, Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT, J. Bone Miner. Res., 28, 736, 10.1002/jbmr.1784 · DOI · Paper page
  23. Hansen, 2012, Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 27, 1794, 10.1002/jbmr.1624 · DOI · Paper page
  24. Sun, 2015, Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats, J Diabetes, 7, 584, 10.1111/1753-0407.12282 · DOI
  25. Nuche-Berenguer, 2009, Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states, Calcif. Tissue Int., 84, 453, 10.1007/s00223-009-9220-3 · DOI · Paper page
  26. Aoyama, 2014, Expression of glucagon-like peptide-1 receptor and glucosedependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells, Int. J. Mol. Med., 34, 475, 10.3892/ijmm.2014.1787 · DOI · Paper page
  27. Hu, 2016, Liraglutide attenuates the osteoblastic differentiation of MC3T3E1 cells by modulating AMPK/mTOR signaling, Mol. Med. Rep., 14, 3662, 10.3892/mmr.2016.5729 · DOI
  28. Pacheco-Pantoja, 2011, Receptors and effects of gut hormones in three osteoblastic cell lines, BMC Physiol., 11, 12, 10.1186/1472-6793-11-12 · DOI · Paper page
  29. Mansur, 2015, Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus, J. Cell. Physiol., 230, 3009, 10.1002/jcp.25033 · DOI · Paper page
  30. Wen, 2018, Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis, Experimental and therapeutic medicine, 15, 5077
  31. Mieczkowska, 2015, Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26, 209, 10.1007/s00198-014-2845-8 · DOI
  32. Hinton, 2009, Weight loss-induced alterations in serum markers of bone turnover persist during weight maintenance in obese men and women, J. Am. Coll. Nutr., 28, 565, 10.1080/07315724.2009.10719788 · DOI · Paper page
  33. Bunck, 2011, Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes, Diabetes Obes. Metab., 13, 374, 10.1111/j.1463-1326.2010.01355.x · DOI · Paper page
  34. Tyrovola, 2015, The “Mechanostat theory” of frost and the OPG/RANKL/RANK system, J. Cell. Biochem., 116, 2724, 10.1002/jcb.25265 · DOI
  35. Strollo, 2017, Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial, Endocrine, 56, 667, 10.1007/s12020-016-1171-7 · DOI
  36. Kang, 2015, Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner, Journal of periodontal & implant science, 45, 101, 10.5051/jpis.2015.45.3.101 · DOI
  37. Tanaka, 2015, Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells, Biochem. Biophys. Res. Commun., 461, 193, 10.1016/j.bbrc.2015.02.091 · DOI · Paper page
  38. Daniele, 2015, Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism, Diabetes Care, 38, 1509, 10.2337/dc14-2989 · DOI · Paper page
  39. Samelson, 2018, Diabetes and deficits in cortical bone density, microarchitecture, and bone size: Framingham HR-pQCT study, J. Bone Miner. Res., 33, 54, 10.1002/jbmr.3240 · DOI · Paper page
  40. Bjarnason, 2002, Mechanism of circadian variation in bone resorption, Bone, 30, 307, 10.1016/S8756-3282(01)00662-7 · DOI · Paper page

Cited by

See all 75

Metadata

Authors
Hygum, K., Harsløf, T., Jørgensen, N. R., Rungby, J., Pedersen, S. B., & Langdahl, B. L.
Venue
Bone
Publisher
Elsevier BV
Published
2020-03
Volume
132
Pages
115197
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W2995094905
Cited by
75
References
20
FWCI
5.21
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Danish Diabetes Academy
  • Aarhus Universitet

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.